Globeflex Capital’s PTC Therapeutics PTCT Stock Holding History

Globeflex Capital’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$486K	Sell	5,956 -1,334	-18%	-$96.3K	0.06%	240
2026 Q1	$497K	Buy	7,290 +31	+0.4%	+$2.19K	0.08%	227
2025 Q4	$551K	Buy	7,259 +5,402	+291%	+$393K	0.08%	230
2025 Q3	$114K	Hold	1,857	–	–	0.02%	361
2025 Q2	$90.7K	Buy	+1,857	New	+$88.2K	0.01%	386
2019 Q1	–	Sell	-3,200	Closed	-$110K	–	459
2018 Q4	$110K	Hold	3,200	–	–	0.03%	400
2018 Q3	$150K	Sell	3,200 -5,600	-64%	-$232K	0.03%	413
2018 Q2	$297K	Buy	+8,800	New	+$274K	0.06%	357
2017 Q1	–	Sell	-23,671	Closed	-$258K	–	518
2016 Q4	$258K	Buy	+23,671	New	+$248K	0.06%	328

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Globeflex Capital's PTCT Position: Q2 2026 in Review

Globeflex Capital reduced its PTC Therapeutics (PTCT) stake by 18% in Q2 2026, selling an estimated $96.3K and leaving 5,956 shares worth $486K. The position accounts for 0.06% of the portfolio, ranked #240.

Globeflex Capital first reported a position in PTCT in Q4 2016 and has held it in 9 quarters since. The position peaked at $551K in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Globeflex Capital held 5,956 shares of PTC Therapeutics worth $486K as of Q2 2026.
Globeflex Capital sold 1,334 PTC Therapeutics shares in Q2 2026, an estimated $96.3K.
PTC Therapeutics made up 0.06% of Globeflex Capital's portfolio in Q2 2026, its #240 holding.
Globeflex Capital first reported a position in PTC Therapeutics in Q4 2016 and has held it in 9 quarters since.
Globeflex Capital's PTC Therapeutics position peaked at $551K in Q4 2025.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Globeflex Capital's 13F filing for Q2 2026, filed 12 Aug 2026.